

2009 PQRI measures groups changes for 2010:

Group: Preventive Care CABG	Changes: Addition of Measure 173: Preventive Care and Screening :Unhealthy Alcohol Use - Reportable through registry-based reporting only
--	---

New measures groups for 2010:

Group: CAD	Measures: (Reportable through registry-based reporting only) 6: Coronary Artery Disease (CAD): Oral Antiplatelet Therapy Prescribed for Patients with CAD 114: Preventive Care and Screening: Inquiry Regarding Tobacco Use 115: Preventive Care and Screening: Advising Smokers and Tobacco Users to Quit 196: Coronary Artery Disease (CAD): Symptom and Activity Assessment 197: Coronary Artery Disease (CAD): Drug Therapy for Lowering LDL-Cholesterol
Group: Heart Failure	Measures: (Reportable through registry-based reporting only) 5: Heart Failure: Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD) 8: Heart Failure: Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD) 114: Preventive Care and Screening: Inquiry Regarding Tobacco Use 115: Preventive Care and Screening: Advising Smokers and Tobacco Users to Quit 198: Heart Failure: Left Ventricular Function (LVF) Assessment 199: Heart Failure: Patient Education
Group: IVD	Measures: 114: Preventive Care and Screening: Inquiry Regarding Tobacco Use 115: Preventive Care and Screening: Advising Smokers and Tobacco Users to Quit 201: Ischemic Vascular Disease (IVD): Blood Pressure Management Control 202: Ischemic Vascular Disease (IVD): Complete Lipid Profile 203: Ischemic Vascular Disease (IVD): Low Density Lipoprotein (LDL-C) Control

204: Ischemic Vascular Disease (IVD): Use of Aspirin or Another Anti-thrombotic

Group:
Hepatitis C

Measures:

84: Hepatitis C: Ribonucleic Acid (RNA) Testing Before Initiating Treatment

85: Hepatitis C: HCV Genotype Testing Prior to Treatment

86: Hepatitis C: Antiviral Treatment Prescribed

87: Hepatitis C: HCV Ribonucleic Acid (RNA) Testing at Week 12 of Treatment

89: Hepatitis C: Counseling Regarding Risk of Alcohol Consumption

90: Hepatitis C: Counseling Regarding Use of Contraception Prior to Antiviral Therapy

183: Hepatitis C: Hepatitis A Vaccination in Patients with HCV

184: Hepatitis C: Hepatitis B Vaccination in Patients with HCV

Group:
HIV/AIDS

Measures:

(Reportable through registry-based reporting only)

159: HIV/AIDS: CD4+ Cell Count or CD4+ Percentage

160: HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis

161: HIV/AIDS: Adolescent and Adult Patients with HIV/AIDS Who Are Prescribed Potent Antiretroviral Therapy

162: HIV/AIDS: HIV RNA Control After Six Months of Potent Antiretroviral Therapy

205: HIV/AIDS: STD Screening for Chlamydia and Gonorrhea

206: HIV/AIDS: STD Screening for High Risk Sexual Behaviors

207: HIV/AIDS: Screening for Injection Drug Use

208: HIV/AIDS: STD Screening for Syphilis

Group:
CAP

Measures:

56: Community-Acquired Pneumonia (CAP): Vital Signs

57: Community-Acquired Pneumonia (CAP): Assessment of Oxygen Saturation

58: Community-Acquired Pneumonia (CAP): Assessment of Mental Status

59: Community-Acquired Pneumonia (CAP): Empiric Antibiotic